Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment

Psychosomatics

Volumn 46, Issue 2, 2005, Pages 131-134

  Pandya, Rupang ^a   Metz, Luanne ^b   Patten, Scott B ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CASE FINDING; CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION RATING SCALE; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RATING SCALE; ADOLESCENT; HOSPITALIZATION; MAJOR DEPRESSION; MIDDLE AGED; OBSERVER VARIATION; PATIENT SELECTION; PREDICTION AND FORECASTING; QUESTIONNAIRE; REPRODUCIBILITY; VALIDATION STUDY;

ADOLESCENT; ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVER VARIATION; PATIENT COMPLIANCE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 17844411224     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.46.2.131     Document Type: Article

References (16)

1. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z: Mood disorders and multiple sclerosis. Arch Neurol 1987; 44:376-378
2. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW: Depression and multiple sclerosis. Neurology 1996; 46:628-632
3. Patten SB, Metz LM, Reimer MM: Biopsychosocial correlates of major depression in a multiple sclerosis population. Multiple Sclerosis 2000; 6:115-120
4. Schiffer RB, Caine ED, Bamford KA, Levy S: Depressive episodes in patients with multiple sclerosis. Am J Psychiatry 1983; 140:1498-1500
5. Minden SL, Orav J, Reich P: Depression in multiple sclerosis. Gen Hosp Psychiatry 1987; 9:426-434
6. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54:531-533
7. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343:898-904
8. Patten SB, Metz LM: Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Multiple Sclerosis 2001; 7:243-248
9. Patten SB, Metz LM: Interferon beta-1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002; 59:744-746
10. Radloff LS: The CES-D scale: a self-report depression scale for research in the general population. Applied Psychol Measurement 1977; 1:385-401
11. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ: Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106:203-214
12. McDowell I, Newell C: Measuring Health, a Guide to Rating Scales and Questionnaires, 2nd ed. New York, Oxford University Press, 1996
13. Blalock SJ, DeVillis RF, Brown GK, Wallston KA: Validity of the Center for Epidemiologic Studies Depression Scale in arthritis research. Arthritis Rheum 1989; 32:991-997
14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, APA, 1994
15. STATA. College Station, Tex, Stata Corporation, 2001
16. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33:1444-1452